IBTA vs PACS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

IBTA

39.7
AI Score
VS
PACS Wins

PACS

54.8
AI Score

Investment Advisor Scores

IBTA

40score
Recommendation
SELL

PACS

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IBTA PACS Winner
Revenue 171.39M 2.85B PACS
Net Income -11.55M 157.06M PACS
Net Margin -6.7% 5.5% PACS
Operating Income -12.71M 229.37M PACS
ROE -4.8% 14.1% PACS
ROA -2.4% 2.8% PACS
Total Assets 485.40M 5.66B PACS
Cash 148.17M 164.45M PACS
Current Ratio 1.71 0.91 IBTA

Relative Price Performance (Last 90 Days)

IBTA 1M: +43.4% · 3M: +18.0% PACS 1M: -1.3% · 3M: +17.2%

Current Technical Phase

IBTA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.1% over 20 days), RSI 59

RSI (14): 58.5 · Price: $37.71

PACS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 47.6 · Price: $44.25

Fundamentals Snapshot

Metric IBTA PACS
Market Cap
Forward P/E 20.0 16.3
Trailing P/E 25.5
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin 0.8% 0.2%
Operating Margin 0.0% 0.1%
EPS -0.45 1.71
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PACS is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.